E-poster - Screening Strategies for TTI

• P-322 • DIAGNOSTIC OF VCJD IN BLOOD: A SECOND GENERATION ASSAY > D. Daisy BOUGARD • P-323 • PRELIMINARY PERFORMANCE CHARACTERISTICS OF A TRANSCRIPTION-MEDIATED AMPLIFICATION BLOOD SCREENING ASSAY ON A FULLY AUTOMATED SYSTEM THAT DETECTS 5 VIRUSES: HIV-1, HIV-2, HCV, HBV AND HEV > K. Kristin LIVEZEY • P-325 • THE PREVALENCE OF HIV, HBV AND HTLV-I/II, IN PATIENTS RECEIVING BLOOD FROM THE SOUTH AFRICAN NATIONAL BLOOD SERVICE. > R. Reynier WILLEMSE
Objectives : The prevalence of HIV, HBV and HTLV in the patient population of the SANBS • P-326 • EVALUATION OF THE SPECIFICITY OF COBAS® BABESIA FOR USE ON THE COBAS® 6800/8800 SYSTEMS IN POOLS OF SIX > J. Jean STANLEY
Objectives : 1) Determine the clinical specificity of cobas® Babesia for use on cobas® 6800/8800 Systems for testing in pools of 6 donation whole blood samples
2) Identify cobas® Babesia detects B. microti, B. duncani, B. divergens, and B. venatorum
3) Understand that the Roche Whole Blood Collection Tube lyses red blood cells and preserves Babesia DNA and RNA and that the sample can be pooled directly from the tube or placed on the cobas® 6800/8800 Systems for testing
• P-327 • PERFORMANCE OF THE VITROS® IMMUNODIAGNOSTIC PRODUCTS ANTI-HTLV I/II ASSAY* IN TWO CLINICAL LABORATORIES > C. Charles Noeson
Objectives : 1.Understand the clinical sensitivity of the VITROS Anti-HTLV compared to the ARCHITECT rHTLV I/II assay
2. Understand the clinical specificity of the VITROS Anti-HTLV compared to the ARCHITECT rHTLV I/II assay • P-328 • DETECTION OF DENGUE RNA IN VIETNAMESE BLOOD DONORS USING COBAS® CHIKV/DENV FOR USE ON THE COBAS® 6800/8800 SYSTEMS > J. Jean STANLEY
Objectives : 1) Determine the prevalence of chikungunya virus (CHIKV) and dengue virus (DENV) in asymptomatic blood donors in Vietnam
2) Determine the specificity of cobas® CHIKV/DENV for use on the cobas® 6800/8800 Systems
3) Demonstrate cobas® CHIKV/DENV is a suitable test for routine screening of blood donors in DENV endemic areas
• P-329 • SCREENING FOR TRANSFUSION TRANSMITTABLE INFECTIONS IN BLOOD DONORS – DUAL PLATFORM EXPERIENCE OF A TERTIARY CARE ONCOLOGY CENTER > A. Amardeep PATHAK • P-330 • DEVELOPMENT AND VALIDATION OF SENSITIVE AND COST EFFECTIVE NUCLEIC ACID TEST TO DETECT HIV1, HIV2, HBV AND HCV IN PLASMA SAMPLES USING MULTIPLEX PCR WITH LIQUID HYBRIDISATION ASSAY (NAT-ELISA) > P. Priyanka SHARMA • P-331 • EVALUATION OF THE SPECIFICITY PROVIDED BY ALINITY S VERSUS PRISM (HBSAG, HCV-AB, HIV-AG/AB) AND ARCHITEC (SYPHILIS-AB) > R. Rocio GONZALEZ DIEZ
Objectives : To improve the management of the initially reactive serological screening results
To improve the specificity of the screening
To minimize the negative impact of the false positive results over the management of blood donors • P-332 • REENTRY OF DEFERRED BLOOD DONORS DUE TO FALSE-POSITIVE SCREENING TESTS RESULTS IN ABBOTT PRISM/ARCHITECT ASSAYS AFTER THE INTRODUCTION OF ABBOTT ALINITY S ASSAYS > M. Manuela MILETIĆ
Objectives : - The selection of mandatory tests to be used for blood donor screening is depending on the prevalence of pathogens in the general and blood donor populations, the ratio of first-time and repeat donors, self-sufficiency in blood supply, and the country’s economic resources.
- Alinity s assays seems to be more specific than Prism/Architect assays. The results of this study showed that 28 blood donors reentered into the donor pool after the retesting with the new screening tests.
- Taking into consideration, that the reentered blood donors were repeat donors and tested over many years of routine screening assays, we found this kind of requalification process for reentering blood donors previously deferred by historically false-positive screening test results acceptable and valuable. • P-333 • PREPAREDNESS FOR WEST NILE VIRUS DONATION SCREENING IN THE NETHERLANDS IN ANTICIPATION OF DIFFERENT OUTBREAK SCENARIOS > A. Anton VAN WEERT • P-334 • TEN YEARS OF FALSE POSITIVE SEROLOGY RESULTS IN A TRANSFUSION CENTER. COULD BLOOD DONOR LOSS BE AVOIDED? > M. María José CANDELA
Objectives : - False positive serologic markers results in blood donations are a problem for blood transfusion centers due to the loss of blood donations and donors that provoke.
- The donors with false positive results usually are different for each method, so when the technique is changed, we should try to recover de excluded donors of the previuos technique, if we don't do so, we will have excluded donors of both techniques.
- Now that we have NAT, It would be necessary to change the way these donors and donations are managed in order to recover all of them. • P-335 • POLISH EXPERIENCE WITH THE ALINITY I ASSAYS FOR DETECTION OF HBSAG, HIV AG/AB, ANTI-HCV AND SYPHILIS DURING EVALUATION AND IN ROUTINE USE > P. Piotr GRABARCZYK • P-336 • EXPERIENCE WITH ALINITY S SYSTEM AFTER ONE YEAR OF ROUTINE WORK > M. Miljana STOJIC VIDOVIC
Objectives : 1.To compare two serology screening testing systems.
2. Importance of specificity in blood donor screening.
3. Reduced unnecessary blood donors deferral due to false positive results.
• P-337 • ASSESSMENT OF THE EFFECTIVENESS OF THE DONOR SELECTION PROCESS THROUGH THE ANALYSIS OF THE PREVALENCE OF HIV, HBV AND HCV IN DONORS COMPARED TO THAT OF THE GENERAL POPULATION (2015-2019) > R. Rocio GONZALEZ DIEZ
Objectives : To preserve the health of donoss and patients
To know the prevalence of infectious markers in new and repeat donors
To know the evolution of the prevalence of the markers during a period of five years • P-338 • PANTHER ART CASE STUDY OF WORKFLOW EFFICIENCY GAINS > R. Ronel RADEMEYER
Objectives : New NAT technology
Work flow efficiency
Work flow comparison • P-339 • EVALUATION OF THE ANALYTICAL SENSITIVITY OF COBAS® MPX FOR USE ON THE COBAS® 6800/8800 SYSTEMS > J. Jean STANLEY
Objectives : 1) Demonstrate the analytical sensitivity for HBV, HCV and HIV-1 Group M of cobas® MPX was verified by three independent tests sites
2) Verify the claimed LODs for HBV and HCV
3) Demonstrate the estimated 50% and 95% LODs overall for HIV were less than the claim
• P-340 • RESIDUAL RISK OF HIV, HEPATITIS B AND HEPATITIS C TRANSMISSION FROM 2009 TO 2017 AT THE PROBOLINGGO INDONESIA RED CROSS BLOOD CENTER > B. Boby MULYADI
Objectives : 1. Aware transfusion safety
2. Improve transfusion safety
3. Calculate estimated residual risk routinely in blood center • P-341 • HIV, HBV AND HCV RESIDUAL RISK IN A REGIONAL BLOOD BANK OF BUENOS AIRES > E. Eulalia RODRIGUEZ • P-342 • COMPARISON OF DUPLICATE NAT REPEATED TESTING BETWEEN EDTA TUBES AND PLASMA FROM BAGS IN THAI BLOOD DONORS > T. Tongjai SAWANGSUB • P-343 • ESTIMATION OF INCIDENCE RATES & RESIDUAL RISKS OF HIV, HBV AND HCV IN INDIAN SETTINGS USING NAT WINDOW PERIOD YIELD CASES > H. Hem PANDEY
Objectives : 1. Blood transfusion safety and NAT testing
2. Window period by different screening assays
2. Calculation of incident rate and residual risk of HIV, HCV AND HBV • P-344 • INCIDENCE OF TTI REACTIVITY IN PARENTAL VERSUS NON-PARENTAL REPLACEMENT BLOOD DONORS: AN EXPERIENCE FROM A PAEDIATRIC TERTIARY CARE CENTRE FROM NORTH INDIA > S. Satyam ARORA
Objectives : 1. Newer insight into parents as replacement donors
2. Data on TTI reactivity among parents as donors for their child
3. Higher TTI reactivity among the parents replacement donors in India • P-345 • FLOW CYTOMETRIC AND INDIRECT IMMUNOFLOUROCENCE IDENTIFICATION OF HSV INFECTED VERO CELLS (AS A MODEL OF HBV) USING QDS AND FITC, INTRODUCING RED AND GREEN IMMUNOFLOUROCENCE AS DEFINITIVE DETECTION > L. Leila MOUSAVI • P-346 • THE EFFECT OF PRE-DONATION LABORATORY SCREENING IN NEW-REGISTERED DONORS ON BLOOD SAFETY > M. Mahtab MAGHSUDLU • P-347 • EVALUATION OF THE ABBOTT ARCHITECT SYPHILIS TP CMIA FOR TREPONEMA PALLIDUM SCREENING AMONG BLOOD DONOR. > N. Norfazlina MOHAMAD • P-348 • PERFORMANCE OF THE ELECSYS CHAGAS ASSAY ON THE NEW COBAS E 801 ANALYSER VERSUS COMMERCIALLY AVAILABLE ASSAYS FOR DETECTION OF ANTIBODIES TO TRYPANOSOMA CRUZI > S. Sigrid Reichhuber • P-349 • EVALUATION OF THE MOSAIQ SEROLOGICAL DISEASE SCREENING MICROARRAY SYSTEM FOR DETECTION OF ANTIBODIES TO TREPONEMA PALLIDUM AND HUMAN CYTOMEGALOVIRUS > J. Janine ROBB
Objectives : To inform listeners of the MosaiQ technology.
To describe the studies performed and the results.
To provide conclusions of the study and the CE Mark achieved.
• P-350 • INCIDENCE AND RESIDUAL RISK OF TRANSFUSION-TRANSMITTED VIRAL INFECTIONS (HBV, HCV, HIV) IN A BLOOD BANK POPULATION FROM NORTH-EAST MEXICO, AFTER NUCLEIC ACID TESTING IMPLEMENTATION > R. Roxana SALDAÑA-VÁZQUEZ
Objectives : 1. to know the incidence of transfusion-transmitted infections in a blood bank in an upper-middle-income country
2. to know the incidence of diagnostic window period in a blood bank in an upper-middle-income country
3. to know the residual risk of TTVI in a blood bank in an upper-middle-income country • P-351 • DONOR DEFERRAL FOR TATTOOING: ARE WE DOING IT RIGHT ? > C. Charumathy ARJUNAN
Objectives :
Among the tattooed blood donors, the number of tattoos acquired by a donor is significantly associated with the risk of harbouring a viral TTI (HIV/HCV/HBV).

However, there was no significant difference between the seroprevalence rate of TTI among the tattooed and non-tattooed blood donors.

In countries like India where tattooing practices are not governed by statutory committees, donor deferral for same should be revised regularly. • P-352 • TRANSFUSION TRANSMISSIBLE INFECTION PREVALENCE IN FIRS AND REPEAT BLOOD DONORS > T. Tatjana MAKAROVSKA BOJADJIEVA
Objectives : Donor selection and self deferral.
Voluntary regular donors, no family/replacement donors.
Blood testing. • P-353 • EVALUATION OF THE AUTOMATED FLUORESCENT IMMUNOASSAY SYSTEM ANTI‑HEPATITIS C VIRUS ASSAY FOR THE DETECTION OF HEPATITIS C VIRUS INFECTION > A. Akhlaaq WAZEER • P-354 • IMPACT OF IMPLEMENTING THE COBAS E 601 ANALYSER FOR ROUTINE SCREENING IN BLOOD BANKS > M. María Isabel BERMÚDEZ FORERO • P-355 • NATSPERT: A MULTIPLEX RT-PCR BASED INDIVIDUAL DONOR NUCLEIC ACID AMPLIFICATION TEST FOR SCREENING BLOOD DONORS FOR TRANSFUSION TRANSMITTED INFECTIONS > K. Kanchan DOGRA
Objectives : 1. The option of a new RT-PCR based ID-NAT option for blood donor screening.
2. In low resource countries, it is extremely important to rely on locally manufactured kits, but, without compromising on the quality.
3. The same kit can also be used for pre-operative patient screening apart from blood donor screening. • P-356 • STRATEGY FOR INFECTIOUS DISEASE SCREENING FACING UNEXPECTED POSIBLE OUTBREAKS: A SINGLE BLOOD CENTRE EXPERIENCE IN SPAIN > L. Laura BIRITXINAGA • P-357 • PERFORMANCE EVALUATION OF SEROLOGY ASSAYS FOR BLOOD BANK SCREENING IN THE DOMINICAN REPUBLIC > C. César MATOS MORONTA • P-358 • SIMULTANEOUS MULTI-ASSAY TESTING ON THE COBAS® 8800 SYSTEM > J. Jean STANLEY
Objectives : 1) Demonstrate that donor blood samples can be tested with multiple assays by individual donation testing (IDT) concurrently and efficiently with the same sample tube on the cobas® 8800 System.
2) Verify the manufacturer’s claim of the instrument’s ability to report 960 test results within an 8-hour work shift.
3) Understand that samples may be continuously added to the cobas® 6800/8800 Systems, as needed for testing and that minimal operator hands-on time is required to run the instrument.
• P-359 • PREVALENCE, INCIDENCE AND RESIDUAL RISK OF HCV, HIV-1 AND HBV INFECTIONS BEFORE THE IMPLEMENTATION OF NUCLEIC ACID SCREENING IN HUNGARY > É. Éva BARABÁS
Objectives :
• P-360 • DESCRIPTIVE STUDY OF INCIDENCE AND SOCIO DEMOGRAPHIC FACTORS RELATED TO TRANSFUSION TRANSMITTED INFECTION AMONG VOLUNTARY BLOOD DONOR POPULATION IN SRI LANKA > I. Imali EDIRIWEERA • P-362 • TRANSFUSION TRANSMITTED INFECTION (TTI) AMONG HEALTHY BLOOD DONORS: A 2-YEAR (2017-2018) SEROPREVALENCE ANALYSIS IN THE BLOOD CENTER OF NORTH ACEH – INDONESIA. > T. Teuku ILHAMI SURYA AKBAR • P-363 • HUMAN IMMUNODEFICIENCY VIRUS, HEPATITIS B AND HEPATITIS C INFECTION TESTING AMONG BLOOD DONORS OF THE BLOOD BANK OF A TERTIARY HOSPITAL USING IMMUNOASSAY AND NUCLEIC ACID AMPLIFICATION TEST > C. Christine AMADA • P-364 • IMPLEMENTATION OF COBAS 8100/8000 AUTOMATED WORKFLOW SERIES AND NEW INFECTIOUS DISEASE TESTING PLATFORM: EXPERIENCE AND FIRST RESULTS > C. Caroline TINGUELY
Objectives : From semi-automation to automation
Experience with a new testing platform
Cobas8100/8000
• P-365 • ANALYTICAL EVALUATION OF THE CHEMILUMINESCENCE METHOD FOR BIOLOGICAL QUALIFICATION OF BLOOD DONATIONS IN VIROLOGY > A. Abderrahim LAOUINA • P-366 • TWENTY SEVEN YEARS EXPERIENCE IN HTLVI/II SCREENING IN LISBON BLOOD CENTER > I. Isabel NEVES
Objectives : Epidemiological Evaluation of HTLV I/ II Screening in Blood Donors of Lisbon Blood Center

Compare HTLV I/II prevalence before and after changing the eligibility criteria
• P-367 • STRATEGY FOR SCREENING AND CONFIRMATION OF HTLV-1/2 INFECTION IN LOW-ENDEMIC AREAS > H. Huimin JI • P-368 • COMPARATIVE STUDY OF INFORMATION METHOD TO BLOOD DONORS OF THE RESULTS WITH NONSPECIFIC REACTIVITIES (NS.R.) IN TWO SEXENIES > A. Ana Maria OJEA
Objectives : 1. If we compare two periods, we can conclude that informing donors of results by post, increases donors by 4% with follow-up.
2. In 2013-2018 period, 9% more donors with negative results than in 2007-2012 period have been accepted after follow-up.
3. Donations rejected by Ns.R. in the first period of time (2007-2012) were 9 and in the second period (2013-2018) were 13 for every 10,000 donations • P-369 • IMPACT OF THE CHANGE OF SEROLOGY TECHNOLOGY IN THE EVOLUTION OF NONSPECIFIC REACTIVITIES (NS.R) OF THE COMMUNITY CENTER OF BLOOD AND TISSUES OF ASTURIAS (SPAIN) > A. Ana Maria OJEA
Objectives : 1.The prevalence of Ns.R. in 2019 with Roche's Cobas 8000e801 equipment, it is 0.34% in 26,602 donations analyzed.
2. The prevalence results analyzed with Cobas 8000e801 in the first year are identical to the first year of the Abbott Prism and Architect technique (0.34%).
3. It is necessary to continue analyzing the data in the coming years to know the evolution of the Ns.R. with the new technology implemented to see if the results go down.
• P-370 • TRENDS IN TRANSFUSION TRANSMISSIBLE INFECTIONS AMONG BLOOD DONORS ATTENDING PRIMARY & SECONDRY HEALTH CARE FACILITY > F. Farhan RASHEED • P-371 • PREVENTION OF TRANSFUSION-TRANSMITTED POSTNATAL CYTOMEGALOVIRUS INFECTION USING LEUKOREDUCED RED BLOOD CELL TRANSFUSION > M. Mconsejo ORTÍ VERDET
Objectives : It`s a study of security transfusional. • P-372 • DETECTING TRANSFUSION TRANSMITTED CONCURRENT INFECTIONS AMONG APPARENTLY HEALTHY BLOOD DONORS FROM NORTH INDIA > M. Manish RATURI
Objectives : 1. To know the prevalence of TTI among blood donors attending our blood centre.
2. To find the prevalence of Concurrent TTI among these serology reactive blood donors [SRBD].
3. To understand the response rate on notifying these SRBD and methods to improve the same in future donors. • P-373 • NOTIFICATION AND RESPONSE RATES OF BLOOD DONORSWITH REACTIVE RESULTS IN SCREENING ‎TESTS (HIV, HEPATITIS B , HEPATITIS C)‎ > L. Leila KASRAIAN • P-374 • TO EVALUATE THE PREVALENCE OF TRANSFUSION TRANSMITTED INFECTIONS SCREENED AT A SINGLE CENTER IN TERTIARY CARE HOSPITAL IN CENTRAL INDIA > A. Ankit JAIN
Objectives : 1. To learn the different patterns of TTIs in different areas of India.
2. To learn about the latest techniques to minimize the TTIs and provide the optimized blood to the recipients.
3. To analyze data from our blood bank and its comparison from different other blood banks. That will also quantify our efficiency in comparison to the other blood banks